Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for M96088105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Toronto Dominion Bank
13G/A
Amendment 1
|
6.7% |
8/12/2026
Event 6/30/2026
|
|
| The Toronto-Dominion Bank | 6.7% | ||
| TD Securities Inc. | 0.2% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 2
|
3.5% |
5/15/2026
Event 3/31/2026
|
|
| Paradigm BioCapital Advisors LP | 3.5% | ||
| Paradigm BioCapital Advisors GP LLC | 3.5% | ||
| Senai Asefaw, M.D. | 3.5% | ||
| Paradigm BioCapital International Fund Ltd. | 3.1% | ||
|
Toronto Dominion Bank
13G
|
5.4% |
5/15/2026
Event 3/31/2026
|
|
| The Toronto-Dominion Bank | 5.4% | ||
| TD Securities Inc. | 0% | ||
| BlackRock, Inc. 13G | 5.2% |
4/27/2026
Event 3/31/2026
|
|
| Toronto Dominion Bank 13G/A Amendment 1 | 4.9% |
2/13/2026
Event 12/31/2025
|
|
| Cowen Financial Products LLC 13G/A Amendment 2 | 0% |
11/14/2025
Event 9/30/2025
|
|
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 1
|
9.0% |
11/14/2025
Event 9/30/2025
|
|
| Paradigm BioCapital Advisors LP | 9.0% | ||
| Paradigm BioCapital Advisors GP LLC | 9.0% | ||
| Senai Asefaw, M.D. | 9.0% | ||
| Paradigm BioCapital International Fund Ltd. | 8.0% | ||
| Toronto Dominion Bank 13G | 6.9% |
11/14/2025
Event 9/30/2025
|
|
|
RA Capital Management, L.P.
13G/A
Amendment 4
|
0% |
8/14/2025
Event 6/30/2025
|
|
| RA Capital Management, L.P. | 0% | ||
| Peter Kolchinsky | 0% | ||
| Rajeev Shah | 0% | ||
| RA Capital Healthcare Fund, L.P. | 0% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.0% |
8/12/2025
Event 8/5/2025
|
|
| Paradigm BioCapital Advisors LP | 5.0% | ||
| Paradigm BioCapital Advisors GP LLC | 5.0% | ||
| Senai Asefaw, M.D. | 5.0% | ||
| Paradigm BioCapital International Fund Ltd. | 4.4% | ||
| Morgan Stanley 13G | 5.4% |
8/6/2025
Event 6/30/2025
|
|
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 1
|
4.7% |
8/5/2025
Event 6/30/2025
|
|
| Soleus Capital Master Fund, L.P. | 4.7% | ||
| Soleus Capital, LLC | 4.7% | ||
| Soleus Capital Group, LLC | 4.7% | ||
| Soleus Capital Management, L.P. | 4.7% | ||
| Soleus GP, LLC | 4.7% | ||
| Guy Levy | 4.7% | ||
| Cowen Financial Products LLC 13G/A Amendment 1 | 6.9% |
7/29/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 |
5.0%
Checked 5% or less
|
7/16/2025
Event 6/30/2025
|
|
|
Soleus Capital Master Fund, L.P.
13G
|
5.0% |
6/16/2025
Event 6/13/2025
|
|
| Soleus Capital Master Fund, L.P. | 5.0% | ||
| Soleus Capital, LLC | 5.0% | ||
| Soleus Capital Group, LLC | 5.0% | ||
| Soleus Capital Management, L.P. | 5.0% | ||
| Soleus GP, LLC | 5.0% | ||
| Guy Levy | 5.0% | ||
| Cowen Financial Products LLC 13G | 5.8% |
6/13/2025
Event 6/9/2025
|
|
|
Monograph Capital Holdings Advisors, LLC
13D/A
Amendment 1
|
1.9% |
6/9/2025
Event 6/5/2025
|
|
| Monograph Capital Partners I, L.P. | 1.8% | ||
| Monograph Capital Partners I GenPar, LP | 1.8% | ||
| Monograph Capital Holdings Advisors, LLC | 1.8% | ||
| Fred Cohen | 1.9% | ||
| Charles Conn | 1.8% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 3
|
7.0% |
5/15/2025
Event 3/31/2025
|
|
| RA Capital Management, L.P. | 7.0% | ||
| Peter Kolchinsky | 7.0% | ||
| Rajeev Shah | 7.0% | ||
| RA Capital Healthcare Fund, L.P. | 7.0% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 2
|
2.8% |
5/12/2025
Event 3/31/2025
|
|
| Adage Capital Management, L.P. | 2.8% | ||
| Robert Atchinson | 2.8% | ||
| Phillip Gross | 2.8% | ||
| Menora Mivtachim Holdings Ltd 13G/A Amendment 9 | 4.99% |
3/17/2025
Event 3/11/2025
|
|
|
Adage Capital Management, L.P.
13G/A
Amendment 1
|
6.9% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 6.9% | ||
| Robert Atchinson | 6.9% | ||
| Phillip Gross | 6.9% | ||
| Morgan Stanley 13G/A Amendment 1 | 1.8% |
2/5/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 746 | $30.3 k |
| 2026 Q2 | 200 | 44.1 M | $1.61 B |
| 2026 Q1 | 182 | 46.4 M | $835 M |
| 2025 Q4 | 179 | 43.7 M | $1.02 B |
| 2025 Q3 | 174 | 44.5 M | $888 M |
| 2025 Q2 | 167 | 43.9 M | $602 M |
| 2025 Q1 | 146 | 41.7 M | $461 M |
| 2024 Q4 | 143 | 37.8 M | $403 M |
| 2024 Q3 | 134 | 35.2 M | $446 M |
| 2024 Q2 | 124 | 40.1 M | $673 M |
| 2024 Q1 | 120 | 28.0 M | $419 M |
| 2023 Q4 | 112 | 22.0 M | $330 M |
| 2023 Q3 | 108 | 17.7 M | $248 M |
| 2023 Q2 | 92 | 13.3 M | $138 M |
| 2023 Q1 | 71 | 12.5 M | $116 M |
| 2022 Q4 | 70 | 13.1 M | $116 M |
| 2022 Q3 | 64 | 13.3 M | $111 M |
| 2022 Q2 | 66 | 13.4 M | $109 M |
| 2022 Q1 | 85 | 14.2 M | $124 M |
| 2021 Q4 | 80 | 14.8 M | $141 M |
| 2021 Q3 | 97 | 14.1 M | $237 M |
| 2021 Q2 | 86 | 14.1 M | $215 M |
| 2021 Q1 | 93 | 14.3 M | $279 M |
| 2020 Q4 | 88 | 14.6 M | $262 M |
| 2020 Q3 | 88 | 15.0 M | $289 M |
| 2020 Q2 | 95 | 14.7 M | $382 M |
| 2020 Q1 | 85 | 14.0 M | $250 M |
| 2019 Q4 | 92 | 14.3 M | $477 M |
| 2019 Q3 | 88 | 14.6 M | $347 M |
| 2019 Q2 | 92 | 14.7 M | $527 M |
| 2019 Q1 | 78 | 13.5 M | $497 M |
| 2018 Q4 | 66 | 9.59 M | $413 M |
| 2018 Q3 | 75 | 9.95 M | $470 M |
| 2018 Q2 | 61 | 9.61 M | $483 M |
| 2018 Q1 | 44 | 9.17 M | $456 M |
| 2017 Q4 | 41 | 6.84 M | $254 M |
| 2017 Q3 | 32 | 4.61 M | $145 M |
| 2017 Q2 | 21 | 4.72 M | $85.2 M |